DELRAY BEACH, FL / ACCESSWIRE / December 11, 2015 / In today's quickly evolving market, small cap stocks increasingly profile as a viable investment for those with a higher risk tolerance. While the global market stirs, newer, smaller companies continue to claim larger portions of industry shares, and surprising names begin to surface as possible leaders in their respective fields.
One company that fits that bill is industrial commodities distributor CD International Enterprises (OTC: CDII). Having recently pivoted in focus from legacy manufacturing in minerals and mining, CDII expanded its scope through partnerships and networking, and in doing so, landed an extraordinary purchase order for over $350M - or 240K tons - worth of copper concentrate over a period of 24 months. The deal instantly established CD International as one of the potential major players in the industry, and shares of the company's stock rose approximately 5,000% in a single day following news of the transaction. This rapid increase not only in share price but in company growth could provide keen investors with the opportunity to stake a potentially life-altering strategic position in such a company.
CD International CEO and Chairman, Dr. James Wang, stated, "we are very excited with this purchase order. We have delivered copper concentrate from Chile and Bolivia to China in the past several years. We have been working very hard...to strategically place ourselves between our suppliers in South America and our buyers in China."
Indeed, by relieving itself of some of its ties to manufacturing, CD International paved the way toward this transaction by becoming more mobile and versatile, exemplified by a partnership with APM Terminal, one of the world's largest port owners that has helped to increase CD International's presence in South America.
Another small cap with big aspirations is Premier Biomedical (OTC: BIEI), Inc. The company focuses on new alternative treatments for a wide range of diseases, with a special focus on breast cancer and alternatives to chemotherapy. A scientist working closely with the company and its resources was recently invited to present findings at the San Antonio Breast Cancer symposium.
Also presenting at the symposium is Tap Immune (OTC: TPIV), a clinical-stage onco-immunology company that announced "robust generation of T-cell immunity" following the use of the company's flagship experimental drug, TPIV 100. Data indicated a high percentage of patients responding to the drug, which could be an indication that Stage II trials may be on the horizon for the company.
Elite Pharmaceuticals (OTC: ELTP) profiles as another small cap stock for investors to keep tabs on. The company's pipeline of proprietary products focuses on the treatment of opioid addiction, an increasingly concerning trend in America. Using sustained release oral formulations of opioids and other abuse-deterrents, ELTP hopes its array of innovative therapies can fill a void in the market for these types of drugs.
Lastly, Amarantus Bioscience Holdings, Inc (OTC: AMBS) announced positive findings in its Phase II trial for Eltoprazine, a new drug for aggressive Alzheimer's patients. The company has been active in presenting findings on the drug at numerous financial and events, including the prestigious ICV Manhattan that hosts 50 chief executives of "innovative growth companies."
Though the field of small cap stocks may be forebodingly large to investors, the leaders of the sector are those making consistent partnerships and advancements while diversifying and mobilizing the scope of their business in order to stay relevant in today's shifting financial landscape. The companies listed above, and particularly companies like CD International, seem to be making huge strides. Those practices paid off for CDII in a $350M business transaction. Investors with a tolerance for risk need look no further for a company with the potential for perhaps limitless future, all while coming with an possibly appealingly low price of entry.
Seraphim Strategies is a third party publisher. Not a registered broker/dealer/analyst/adviser, holds no investment licenses and may not sell, offer to sell or offer to buy any security. Market updates, news alerts and corporate profiles are not a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is not to be interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. For full disclaimer please read http://tomorrowsbluechips.com/disclaimer/ This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.
"Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may," "future," "plan" or "planned," "will" or "should," "expected," "anticipates," "draft," "eventually," or "projected." You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements.
SOURCE: Seraphim Strategies LLC
